Ms. Melincoff has over 25 years of leadership experience in the biotechnology and pharmaceutical industries. Her experience has spanned public and private company boards, venture financing, business development, licensing, mergers and acquisitions, research operations, marketing, product management and project management. She is managing director of Gemini Advisors LLC, a consultancy offering assistance to biotech/pharma companies with respect to strategy, licensing, fundraising and other activities.
Ms. Melincoff currently sits on the board of directors of Collegium Pharmaceutical, Inc., Soleno Therapeutics, and Protalix Biotherapeutics and is a Venture Advisor at Agent Capital. She is also a business advisor to Verge Genomics and was a board member at Photocure ASA from 2017-2020 and Tobira Therapeutics from 2014-2016 when Allergan acquired it for $1.7B. From August 2014 to September 2016, she served as Vice President of Business Development at BTG International Inc. a UK- specialist healthcare company.
From September 2004 to the December 2013, Ms. Melincoff was Senior Vice President of Business Development at Shire Pharmaceuticals. Additionally, she led the Strategic Investment Group (SIG), Shire’s $50MM corporate venture fund which was started in 2010. She served as a board member/board observer at DBV Technologies, AM Pharma, ArmaGen Technologies, Promethera Biosciencs, Naurex Inc. (acquired by Allergan) and Enterome. During her tenure, she was involved in numerous licenses, product divestments, co-promotion and collaboration agreements, and mergers and acquisitions. She was responsible for the collaboration with New River Pharmaceuticals that led to the $2.6 billion acquisition of the company within two years of the first transaction. Ms. Melincoff was named a “Top Women in Biotech 2013” by Fierce Biotech as well as being named to the Powerlist 100 of Corporate Venture Capital in 2012 and 2013.
Prior to joining Shire, Ms. Melincoff was Vice President of Business Development at Adolor Corporation, a biopharmaceutical company focused on the development of pain management products that was acquired by Cubist Pharmaceuticals and then Merck. Over the five years that Ms. Melincoff worked at Adolor, the company grew from 22 employees to over 150 employees. She was involved in helping the company launch a successful IPO and in raising over $300 million.
Ms. Melincoff has a B.S in Biology, a Master of Science in Management, and has attained the designation of the Certified Licensing Professional (CLP™).